ViroPharma To Participate In Two December Healthcare Investor Conferences

  ViroPharma To Participate In Two December Healthcare Investor Conferences

PR Newswire

EXTON, Pa., Nov. 29, 2012

EXTON, Pa., Nov.29, 2012 /PRNewswire/ --ViroPharma Incorporated (Nasdaq:
VPHM) today announced that Vincent Milano, president and chief executive
officer of ViroPharma, will present at the Deutsche Bank dbAccess BioFest 2012
Conference at 9:00 AM ET on Monday, December 3, 2012. The conference is being
held at the Four Seasons Hotel in Boston.

ViroPharma also announced that Charles Rowland, vice president and chief
financial officer of ViroPharma, will present at the Oppenheimer 23rd Annual
Healthcare Conference at 1:35 PM ET on Thursday, December 13, 2012. The
conference is being held at the Waldorf=Astoria Hotel in New York City.

ViroPharma's presentations will be webcast live for investors through
www.viropharma.com and available for a period of 14 days following the
conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company
committed to developing and commercializing novel solutions for physician
specialists to address unmet medical needs of patients living with diseases
that have few if any clinical therapeutic options. ViroPharma is developing a
portfolio of therapeutics for rare and Orphan diseases including C1 esterase
inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency; and
recurrent C. difficile infection (CDI). Our goal is to provide rewarding
careers to employees, to create new standards of care in the way serious
diseases are treated, and to build international partnerships with the
patients, advocates, and health care professionals we serve. ViroPharma's
commercial products address diseases including hereditary angioedema (HAE),
seizures and C. difficile-associated diarrhea (CDAD); for full U.S.
prescribing information on our products, please download the package inserts
at http://www.viropharma.com/Products.aspx; the prescribing information for
other countries can be found at www.viropharma.com.

ViroPharma routinely posts information, including press releases, which may be
important to investors in the investor relations and media sections of our
company's web site, www.viropharma.com. The company encourages investors to
consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated

Website: http://www.viropharma.com
Contact: Robert A. Doody Jr., Assistant Director, Investor Relations,
+1-610-321-6290
 
Press spacebar to pause and continue. Press esc to stop.